Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants
Study Identifier:
ALXN2030-HV-101
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Recruitment Complete
Study Details
Medical Condition
- Other
Study Drug
- Drug: ALXN2030
- Drug: Placebo
Date
Aug 2022 - Oct 2026
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 60 Years
Requirements Information
Sex
Female & Male
Age
18 - 60 Years
Study Details
Medical Condition
- Other
Study Drug
- Drug: ALXN2030
- Drug: Placebo
Date
Aug 2022 - Oct 2026
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 60 Years years
Requirements Information
Protocol Summary
The primary purpose of this study is to assess the safety and tolerability of single ascending doses of ALXN2030 in healthy participants.
Trial Locations
Location
Status
Location
Research Site
Harrow, United Kingdom, HA1 3UJ
Status
N/A